New Genomics England industry & clinical interpretation partnerships

26 March 2015

Genomics England, the NHS-owned company established to deliver the 100,000 Genomes Project (100KGP), has announced a new, multi-partner collaborative industrual initiative intended to accelerate the development of new diagnostics and treatments.

The  new Genomics Expert Network for Enterprises (GENE) Consortium comprises ten pharma and biotech companies who will work together on a year-long trial designed to find the best ways of integrating industry expertise to the 100KGP, maximising the potential outputs. Bioinformatics companies specialising in analysis of genomic datasets will also be involved. The initial ten companies are:

  • AbbVie
  • Alexion Pharmaceuticals
  • AstraZeneca
  • Biogen
  • Dimension Therapeutics 
  • GSK
  • Helomics
  • Roche
  • Takeda
  • UCB (reportedly subject to contract negotiation and signature)

Executive Chairman of Genomics England Sir John Chisholm said: “This year we will explore how companies, clinicians and researchers can work together on the 100,000 Genomes Project – giving us a platform to expand and build upon”.

He told the Financial Times: “Genetics [is] going to change the world in the 21st century”.

Genomics England simultaneously announced the specific areas to be explored by the Clinical Interpretation Partnerships (GeCIPs) as an additional research programme to accelerate biomedical discoveries in cancer and rare disease from the 100KGP data. 

The GeCIPs are partnerships between NHS Genomic Medicine Centres, academia and industry. 28 of the initial 88 applications to form GeCIPs have been successful, covering diseaseareas ranging from cancer and cardiovascular disease to paediatric and neurological conditions as well as additional elements such as ethics, law, social science and health economics.

More from us

Genomics and policy news